A Study of Single and Repeated Doses of LY3556050 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

106

Participants

Timeline

Start Date

September 14, 2016

Primary Completion Date

June 2, 2017

Study Completion Date

June 2, 2017

Conditions

Healthy

Interventions

DRUG

LY3556050

Administered orally.

DRUG

Placebo

Administered orally.

Trial Locations (1)

Medpace Clinical Pharmacology, LLC, Cincinnati

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT05341102 - A Study of Single and Repeated Doses of LY3556050 in Healthy Participants | Biotech Hunter | Biotech Hunter